[go: up one dir, main page]

WO2003000738A3 - Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats - Google Patents

Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats Download PDF

Info

Publication number
WO2003000738A3
WO2003000738A3 PCT/EP2002/006764 EP0206764W WO03000738A3 WO 2003000738 A3 WO2003000738 A3 WO 2003000738A3 EP 0206764 W EP0206764 W EP 0206764W WO 03000738 A3 WO03000738 A3 WO 03000738A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibiotic
amino sugar
water
polysaccharide
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/006764
Other languages
English (en)
French (fr)
Other versions
WO2003000738A2 (de
Inventor
Klaus Sommermeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Deutschland GmbH
Original Assignee
Fresenius Kabi Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland GmbH filed Critical Fresenius Kabi Deutschland GmbH
Priority to AU2002328294A priority Critical patent/AU2002328294A1/en
Priority to CA002446205A priority patent/CA2446205A1/en
Priority to US10/481,597 priority patent/US7115576B2/en
Priority to EP02762293A priority patent/EP1397162A2/de
Priority to JP2003507141A priority patent/JP2004534086A/ja
Publication of WO2003000738A2 publication Critical patent/WO2003000738A2/de
Publication of WO2003000738A3 publication Critical patent/WO2003000738A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C08B35/06—Ether-esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/02—Esters
    • C08B31/04—Esters of organic acids, e.g. alkenyl-succinated starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
    • C08B31/125—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch having a substituent containing at least one nitrogen atom, e.g. cationic starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/16—Ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C08B33/02—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C08B33/04—Ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • C08B33/06—Ether-esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C08B35/02—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B35/00—Preparation of derivatives of amylopectin
    • C08B35/04—Ethers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Es sollten neue Arzneiformen für die aminozuckerhaltigen Antibiotika Amphotericin B, Daunorubicin und Doxorubicin bereitgestellt werden, bei welchen die bekannten Nebenwirkungen reduziert und welche unkompliziert anwendbar sind. Das Antimykotikum Amphotericin B ist nephrotoxisch. Die Cytostatika Daunorubicin und Doxorubicin sind stark kardiotoxisch. Die neuen Arzneiformen sind Antibiotika-Stärke-Konjugate, wobei das Antibiotikum mit dem Polysaccharid an dessen reduzierendem Ende über eine Peptidbindung verknüpft ist. Verfahrensmässig erfolgt diese Bindung über J2-Oxidation des Stärkederivats an seinem reduzierenden Ende in wässriger alkalischer Lösung und anschliessender Kopplung des so oxidierten Stärkederivats an das Antibiotikum in organischer Lösung. Die erhaltenen Konjugate sind weniger toxisch. Der Polysccharid-Anteil ist durch Serum-α-Amylase abbaubar und die Peptidbindung einem enzymatischen Angriff zugänglich.
PCT/EP2002/006764 2001-06-21 2002-06-19 Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats Ceased WO2003000738A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002328294A AU2002328294A1 (en) 2001-06-21 2002-06-19 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
CA002446205A CA2446205A1 (en) 2001-06-21 2002-06-19 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
US10/481,597 US7115576B2 (en) 2001-06-21 2002-06-19 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
EP02762293A EP1397162A2 (de) 2001-06-21 2002-06-19 Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats
JP2003507141A JP2004534086A (ja) 2001-06-21 2002-06-19 ポリサッカライド抱合体の形でアミノ糖を含む水溶性抗生物質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129369.0 2001-06-21
DE10129369A DE10129369C1 (de) 2001-06-21 2001-06-21 Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats

Publications (2)

Publication Number Publication Date
WO2003000738A2 WO2003000738A2 (de) 2003-01-03
WO2003000738A3 true WO2003000738A3 (de) 2003-08-28

Family

ID=7688583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006764 Ceased WO2003000738A2 (de) 2001-06-21 2002-06-19 Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats

Country Status (9)

Country Link
US (1) US7115576B2 (de)
EP (1) EP1397162A2 (de)
JP (1) JP2004534086A (de)
CN (1) CN1596129A (de)
AU (1) AU2002328294A1 (de)
CA (1) CA2446205A1 (de)
DE (1) DE10129369C1 (de)
PL (1) PL366438A1 (de)
WO (1) WO2003000738A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
RU2328505C2 (ru) 2002-09-11 2008-07-10 Фрезениус Каби Дойчланд Гмбх Полипептиды, обработанные has, особенно эритропоэтин, обработанный has
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
DE10256558A1 (de) * 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10302520A1 (de) * 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10324710A1 (de) 2003-05-30 2004-12-16 Supramol Parenteral Colloids Gmbh Stärkederivatkomplexe
EP1653991A2 (de) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Durch oxime als bindungsgruppe verbundene konjugate eines polymers mit einem protein
BRPI0413450A (pt) * 2003-08-08 2006-10-17 Fresenius Kabi De Gmbh conjugados de hidroxialquil amido e g-csf
EP2336192A1 (de) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt.
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
CN1929865B (zh) * 2004-03-11 2011-11-16 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
CA2598528A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
CN101045163B (zh) * 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
DE102006020035A1 (de) * 2006-04-26 2007-10-31 B. Braun Melsungen Ag Herstellung und Verwendung von Poly(hydroxyethylstärke)chitin- und Poly(Carboxymethylstärke)chitin-Verbindungen
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
CN100569296C (zh) * 2007-09-17 2009-12-16 重庆莱美药业股份有限公司 一种抗癌前药及其制备方法和用途
EP2070951A1 (de) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern
EP2070950A1 (de) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkylstärkederivate und deren Herstellungsverfahren
BRPI0913007A2 (pt) 2008-05-02 2019-09-24 Novartis Ag moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011061747A1 (en) 2009-11-23 2011-05-26 Conjugate Ltd. Antifungal and anti parasitic conjugates of amphotericin b derivatives
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
EP2590680A1 (de) * 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Konjugate mit hydroxyalkylstärke und einem zytotoxischen mittel sowie verfahren zu ihrer herstellung
WO2013022328A1 (en) 2011-08-09 2013-02-14 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
CN104055787B (zh) * 2013-07-25 2017-04-26 北京蓝贝望生物医药科技股份有限公司 药用水溶性抗真菌大分子化合物
JP7377791B2 (ja) 2017-07-07 2023-11-10 エピセントアールエックス，インコーポレイテッド 治療剤の非経口投与のための組成物
CN110669087B (zh) * 2018-07-02 2023-03-31 上海医药工业研究院 两性霉素b肽衍生物及其制备方法
US11028113B2 (en) * 2018-10-26 2021-06-08 Wisconsin Alumni Research Foundation Cyphomycin, compositions and uses thereof
WO2020119773A1 (zh) * 2018-12-13 2020-06-18 上海医药工业研究院 两性霉素b肽衍生物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414513A (en) * 1977-07-01 1979-02-02 Kyowa Hakko Kogyo Co Ltd Novel composition
EP0428486A1 (de) * 1989-11-15 1991-05-22 Sandoz Ltd. Polymyxinkonjugate
WO1994007536A2 (en) * 1992-09-25 1994-04-14 Keele University Alginate-bioactive agent conjugates
WO1998001158A2 (de) * 1996-07-08 1998-01-15 Fresenius Ag Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
WO1998056424A1 (en) * 1997-06-12 1998-12-17 Ml Laboratories Plc Biologically active materials
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
WO2000078355A2 (en) * 1999-06-18 2000-12-28 Ml Laboratories Plc Biologically active materials
WO2002002146A2 (en) * 2000-07-01 2002-01-10 Ml Laboratories Plc Dextrin-amphotericin conjugates and their methods of preparation
WO2002080979A2 (de) * 2001-03-16 2002-10-17 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-wirkstoff-konjugate
WO2002090390A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939016A (en) 1996-08-22 1999-08-17 Quantum Catalytics, L.L.C. Apparatus and method for tapping a molten metal bath

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414513A (en) * 1977-07-01 1979-02-02 Kyowa Hakko Kogyo Co Ltd Novel composition
EP0428486A1 (de) * 1989-11-15 1991-05-22 Sandoz Ltd. Polymyxinkonjugate
WO1994007536A2 (en) * 1992-09-25 1994-04-14 Keele University Alginate-bioactive agent conjugates
WO1998001158A2 (de) * 1996-07-08 1998-01-15 Fresenius Ag Hämoglobin-hydroxyethylstärke-konjugate als sauerstoff-transport-mittel
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
WO1998056424A1 (en) * 1997-06-12 1998-12-17 Ml Laboratories Plc Biologically active materials
WO2000078355A2 (en) * 1999-06-18 2000-12-28 Ml Laboratories Plc Biologically active materials
WO2002002146A2 (en) * 2000-07-01 2002-01-10 Ml Laboratories Plc Dextrin-amphotericin conjugates and their methods of preparation
WO2002080979A2 (de) * 2001-03-16 2002-10-17 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-wirkstoff-konjugate
WO2002090390A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CERA C ET AL: "WATER-SOLUBLE POLYSACCHARIDE ANTHRACYCLINE CONJUGATES BIOLOGICAL ACTIVITY", ANTI-CANCER DRUG DESIGN, vol. 7, no. 2, 1992, pages 143 - 151, XP000791063, ISSN: 0266-9536 *
DATABASE WPI Section Ch Week 197911, Derwent World Patents Index; Class A96, AN 1979-20500B, XP002238925 *
EHRENFREUND-KLEINMAN T ET AL: "Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 23, no. 5, 1 March 2002 (2002-03-01), pages 1327 - 1335, XP004334096, ISSN: 0142-9612 *
FALK RAMA ET AL: "A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 43, no. 8, August 1999 (1999-08-01), pages 1975 - 1981, XP002182534, ISSN: 0066-4804 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
US7115576B2 (en) 2006-10-03
PL366438A1 (en) 2005-02-07
US20040180858A1 (en) 2004-09-16
CA2446205A1 (en) 2003-01-03
AU2002328294A1 (en) 2003-01-08
EP1397162A2 (de) 2004-03-17
WO2003000738A2 (de) 2003-01-03
JP2004534086A (ja) 2004-11-11
DE10129369C1 (de) 2003-03-06
CN1596129A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
WO2003000738A3 (de) Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
CA2368501A1 (en) High purity maltose process and products
WO2001082971A3 (en) Cyclodextrin containing glycopeptide antibiotic compositions
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
WO2000059528A8 (en) Desleucyl glycopeptide antibiotics and methods of making same
WO2006082184A3 (en) Conjugates of a polypeptide and a pentasaccharide
WO2007079147A3 (en) A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2001039726A3 (en) Antimicrobial 2-deoxystreptamine compounds
WO2002017885A3 (en) Controlled release formulation of erythromycin or a derivative thereof
WO2008077956A3 (en) Oligonucleotide-, protein and/or peptide-polymer conjugates
AU4397700A (en) Combined preparations comprising anthracycline derivatives
WO2002056915A3 (en) Complex of modafinil and cyclodextrin
EP1506780A3 (de) Pharmazeutische Zusammensetzungen enthaltend Macroliden allein oder in Kombination mit anderen pharmazeutischen Wirkstoffen
WO2004008101A3 (en) The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
WO2006044771A3 (en) Methods and compositions for reducing toxicity of a pharmaceutical compound
WO2004108747A3 (de) Lektin-konjugate
WO2004050710A3 (de) Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen
WO2002042315A3 (en) Macrolide solvates
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
WO2001098327A3 (en) Glycopeptide carboxy-saccharide derivatives
AUPR874601A0 (en) Selective targeting of apoptotic cells
YU46503A (sh) Farmaceutski oblik dronedarona za parenteralnu upotrebu
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
AU6377800A (en) Compositions comprising xet and a polysaccharide and/or oligosaccharide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002762293

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2446205

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2013/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 028121953

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003507141

Country of ref document: JP

Ref document number: 10481597

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002762293

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642